Haoma Medica

Haoma Medica is a private, clinical-stage biotech developing NaQuinate (Osteopura), a novel oral therapeutic for osteoporosis and osteopenia. The compound is a naturally occurring vitamin K catabolite that uniquely regulates both bone-building osteoblasts and bone-resorbing osteoclasts, aiming to improve bone quality and quantity with a favorable safety profile. The company has completed a Phase I safety study and holds an international patent portfolio, positioning it to address a large market with significant unmet need due to poor adherence to current therapies. Its strategy includes advancing clinical proof-of-concept studies while commercializing early-stage nutraceutical products.

Platform based on NaQuinate, a naturally occurring vitamin K catabolite small molecule. It has a unique dual-action mechanism regulating both bone-forming osteoblasts (via Wnt/β-catenin pathway) and bone-resorbing osteoclasts (via osteoprotegerin upregulation), designed for oral administration.

Competes in the crowded osteoporosis market dominated by generic bisphosphonates (alendronate) and injectable biologics (denosumab, romosozumab). Key differentiation is oral administration and a unique dual-action mechanism aiming for better safety and efficacy on bone quality. Must demonstrate clear advantages to overcome entrenched treatment patterns.